Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P568: Does infliximab therapy increase incidence of tuberculosis in patients with inflammatory bowel disease in an endemic area: a nationwide study from ChinaECCO '17 Barcelona
Year: 2017
Authors:

Ye L., Liu J., Lin Z., Cao Q.

Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

P569: Sequential rescue treatments in steroid refractory ulcerative colitis: two-year follow-upECCO '17 Barcelona
Year: 2017
Authors:

Protic M.*1, Seibold F.2,3, Manser C.4, Frei P.5, Mottet C.6, Juillerat P.7, Knezevic T.1, Rogler G.4, Beglinger C.8, Schoepfer A.9, Vavricka S.10

1University Hospital Zvezdara, Department of Gastroenterology, Belgrade, Serbia 2Cantonal Hospital Fribourg, Division of Gastroenterology and Hepatology, Fribourg, Switzerland 3Lindenhofspital, Crohn Colitis Center, Bern, Switzerland 4University Hospital Zurich, Department of Gastroenterology, Zurich, Switzerland 5See Spital, Department of Gastroenterology, Zürich, Switzerland 6Hospital Neuchâtel, Department of Gastroenterology, Neuchâtel, Switzerland 7University Hospital Bern, Gastroenterology and Hepatology, Bern, Switzerland 8University Hospital Basel, Division of Gastroenterology & Hepatology, Basel, Switzerland 9Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland 10Stadtspital Triemli, Department of Gastroenterology, Zürich, Switzerland

P570: Current status of the effectiveness of infliximab in patients with ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Yokoyama K.*1, Kawagishi K.1, Kobayashi K.2, Koizumi W.1

1Kitasato University School of Medicine, Department of Gastroenterology, Sagamihara, Japan 2Kitasato University School of Medicine, Research and Development Center for New Medical Frontiers, Sagamihara, Japan

P571: Can Crohn's colits be cured by surgery?ECCO '17 Barcelona
Year: 2017
Authors:

Calafiore A., Sgambato D., Rizzello F., Calabrese C., Poggioli G., Laureti S., Calandrini L., Mazza M., Praticò C., Salice M., Campieri M., Gionchetti P.

University of Bologna, Dept of Clinical and Surgical Sciences - IBD Unit, Bologna, Italy

P572: Medical therapies for stricturing Crohn's disease: efficacy and cross-sectional imaging predictors of therapeutic failureECCO '17 Barcelona
Year: 2017
Authors:

Campos C.1, Perrey A.2, Lambert C.3, Pereira B.3, Goutte M.1,4, Goutorbe F.1,5, Dubois A.6, Reymond M.1, Allimant C.1, Dapoigny M.1, Bommelaer G.1,4, Hordonneau C.2, Buisson A.*1,4

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France 2University Hospital Estaing, Radiology Department, Clermont-Ferrand, France 3University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France 4UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France 5Hospital of Bayonne, Gastroenterology Department, Bayonne, France 6CHU Estaing, Department of Digestive surgery, Clermont-Ferrand, France

P573: Impact of the duration of combination therapy on clinical and pharmacological efficacy of infliximab in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Vernet C., Roblin X., Williet N.

CHU, LOIRE, Saint Etienne, France

P574: Limitations and difficulties in using anti-TNF-alpha agents in inflammatory bowel disease. A survey of the Italian Group for Inflammatory Bowel Disease (IG-IBD)ECCO '17 Barcelona
Year: 2017
Authors:

Saibeni S.*1, Bezzio C.1, Armuzzi A.2, Bossa F.3, Calabrese E.4, Caprioli F.5, Daperno M.6, Mocciaro F.7, Orlando A.8, Papi C.9, Rispo A.10, Rizzello F.11 IG-IBD

1ASST Rhodense, Gastroenterology Unit, Rho, Italy 2Policlinico Gemelli, Rome, Italy 3Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy 4Policlinico Tor Vergata, Rome, Italy 5University of Milan, Milan, Italy 6Ospedale Mauriziano, Torino, Italy 7Ospedale Arnas Civico, Palermo, Italy 8Ospedale Cervello, Palermo, Italy 9Ospedale San Filippo Neri, Rome, Italy 10Policlinico Federico II, Naples, Italy 11University of Bologna, Bologna, Italy

P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patientsECCO '17 Barcelona
Year: 2017
Authors:

Ladic A., Bozina N., Cukovic-Cavka S., Krznaric Z.

University Hospital Centre Zagreb, Zagreb, Croatia

P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?ECCO '17 Barcelona
Year: 2017
Authors:

Piotrowicz G.*1, Kowerzanow J.2, Banaszkiewicz P.2, Babicki A.2, Kot J.3, Rydzewska G.4

1Self-Dependet Health Care Unit of Ministry of Iterior, Gastroenetrology, Gdansk, Poland 2Self-Dependent Health Care Unit of Ministry of Interior, Surgery, Gdansk, Poland 3UCMMiT, Clinic Hyperbaric Medicine and Sea Rescue, Gdynia, Poland 4Central Clinical Hospital of the Ministry of Interior of Warsaw, Gastroenterology, Warsaw, Poland

P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriersECCO '17 Barcelona
Year: 2017
Authors:

Bryant R.*1,2, Costello S.1,3, Schoeman S.4, Sathananthan D.4, Lau S.3, Schoeman M.4, Mountifield R.1,5, Tee D.6, Travis S.7,8, Andrews J.1,9

1University of Adelaide, School of Medicine, Adelaide, Australia 2Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia 3Queen Elizabeth Hospital, Department of Gastroenterology, Adelaide, Australia 4Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia 5Flinders Medical Centre, Department of Gastroenterology, Adelaide, Australia 6Lyell McEwin Hospital, Department of Gastroenterology, Adelaide, Australia 7Oxford University Hospital NHS Trust - John Radcliffe Hospital, Department of Transitional Gastroenterology, Oxford, United Kingdom 8University of Oxford, Oxford, United Kingdom 9Royal Adelaide Hospital, Department of Gastroenteorlogy and Hepatology, Adelaide, Australia

P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Hartery K., Moran C., Sheridan J., Keegan D., Byrne K., Horgan G., Doherty G., Cullen G., Buckley M., Mulcahy H.

St. Vincent's University Hospital, Gastroenterology Department, Dublin, Ireland

P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutationECCO '17 Barcelona
Year: 2017
Authors:

Zambrano Perez A.*1, Elawad M.2, Kiparissi F.1, Shah N.1, Chadokufa S.1, Sider S.1, Huggett B.1

1Great Ormond Street Hospital for Children, Department of Gastroenterology, London, United Kingdom 2Sidra Medical and Research Center, Inflammatory Bowel Disorders Section, Doha, Qatar

P580: Prognostic factors, effectiveness and safety of endoscopic balloon dilatation for de novo and anastomotic strictures in Crohn's disease – a multicenter “real life” studyECCO '17 Barcelona
Year: 2017
Authors:

Balint A.*1, Torocsik D.1, Palatka K.2, Szepes Z.1, Szucs M.3, Ferenci T.4, Nagy F.1, Farkas K.1, Fábián A.1, Bor R.1, Milassin A.1, Rutka M.1, Molnar T.1

1University of Szeged, First Department of Medicine, Szeged, Hungary 2University of Debrecen, Department of Internal Medicine II, Debrecen, Hungary 3University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary 4Óbuda University, John von Neumann Faculty of Informatics, Budapest, Hungary

P581: Highly purified eicosapentaenoic acid, as free fatty acid, reduces fecal calprotectin levels and prevents clinical relapse in ulcerative colitis patients: a double-blind, randomized, placebo controlled trialECCO '17 Barcelona
Year: 2017
Authors:

Scaioli E., Sartini A., Bellanova M., Campieri M., Festi D., Bazzoli F., Belluzzi A.

S Orsola Malpighi Hospital-University of Bologna, Department of Medical and Surgical Sciences, Gastroenterology Unit, Bologna, Italy

P582: The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016ECCO '17 Barcelona
Year: 2017
Authors:

Han S., Kim S., Kim J., Kwon D.-H., Choi J.-S., Yoon S.-R., Yun S.-H., Kim D.-S., Bae J.-H., Choi H.-J., Sung H.-Y., Yoon S.-W.

Celltrion Healthcare Co., Ltd, Incheon, South Korea

P583: Trends in endoscopy management after surgery in a national cohort of Spanish Crohn's disease patients. Results from PRACTICROHN studyECCO '17 Barcelona
Year: 2017
Authors:

Barreiro-de Acosta M.*1, Iborra M.2, García V.3, Gutiérrez A.4, Garcia S.5, Domènech E.6, Martín Arranz M.D.7, Cea-Calvo L.8, Romero C.8, Juliá B.8

1Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain 2Servicio de Gastroenterologia, Hospital La Fe, Valencia, Spain 3Hospital Universitario Reina Sofia, Unidad Clinica de Aparato Digestivo, Cordoba, Spain 4Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain 5Departamento de Gastroenterología, Hospital Miguel Servet, Zaragoza, Spain 6Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain 7Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain 8MSD Spain, Medical Department, Madrid, Spain

P584: A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?ECCO '17 Barcelona
Year: 2017
Authors:

Rasmussen M.*1, Brynskov J.1, Ainsworth M.A.1, Buhl S.1, Bendtzen K.2, Steenholdt C.1

1Copenhagen University Hospital Herlev, Department of Gastroenterology, Herlev Copenhagen, Denmark 2Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark

P585: Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategyECCO '17 Barcelona
Year: 2017
Authors:

Sambuelli A.*1, Bellicoso M.2, Negreira S.2, Goncalves S.2, Huernos S.2, Chavero P.2, Tirado P.2, Cabanne A.3, Gil A.2

1Hospital Bonorino Udaondo, IBD Section - Medicine, Buenos Aires, Argentina 2IBD Section - Hospital Bonorino Udaondo, Medicine, Buenos Aires, Argentina 3Hospital Bonorino Udaondo, Pathology Department, Buenos Aires, Argentina

P586: A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experienceECCO '17 Barcelona
Year: 2017
Authors:

Plevris N., Deekae A., Jones G.R., Manship T.A., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

NHS Lothian - Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom

P587: Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controlsECCO '17 Barcelona
Year: 2017
Authors:

McGowan M.1, Kokkorou M.2, Rebull M.1, Koh Y.3, Gaya D.R.4, Hansen R.5, Russell R.K.5, Gerasimidis K.*1

1University of Glasgow, Human Nutrition, Glasgow, United Kingdom 2University Of Glasgow, Human Nutrition, Glasgow, United Kingdom 3University of Glasgow, Glasgow, United Kingdom 4Glasgow Royal Infirmary, Gastroenterology Unit, Glasgow, United Kingdom 5The Royal Hospital for Children Glasgow, Paediatric Gastroenterology, Glasgow, United Kingdom